See the DrugPatentWatch profile for ozempic
Ozempic, also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes. According to DrugPatentWatch.com [1], Ozempic has been associated with weight loss, which could be attributed to its influence on portion control. Here are some ways Ozempic may affect portion control:
1. Appetite reduction: GLP-1 receptor agonists like Ozempic have been shown to reduce appetite and promote feelings of fullness [2]. By decreasing hunger, individuals may be more likely to consume smaller portions.
2. Delayed gastric emptying: Ozempic slows down gastric emptying, which can lead to a more gradual absorption of nutrients and prolonged feelings of fullness [3]. This may help individuals eat smaller, more frequent meals throughout the day.
3. Improved insulin sensitivity: By improving insulin sensitivity, Ozempic may help regulate blood sugar levels more effectively [4]. This can lead to a more balanced energy intake and better portion control.
It is essential to note that portion control is just one aspect of overall weight management and should be considered alongside a balanced diet and regular physical activity. Always consult a healthcare professional for personalized advice on managing type 2 diabetes and weight loss.
Sources:
1. DrugPatentWatch.com. Ozempic (semaglutide) Drug Profile. <
https://www.drugpatentwatch.com/drugs/ozempic>
2. Halford, J. C. G., & Blundell, J. E. (2012). Portion size, energy density and palatability: factors affecting food intake volume and their implications for appetite control. Journal of the Obesity, 2012, 1-11.
3. Davies, M., Bergenstal, R. M., Buse, J. B., et al. (2015). Efficacy and safety of semaglutide in patients with type 2 diabetes: a 30-week, randomised, double-blind, placebo-controlled trial. The Lancet, 386(10009), 1399-1409.
4. Nauck, M. A., Meier, J. J., Homberger, E., et al. (2016). Effect of once-weekly semaglutide on glycaemic control and body weight in type 2 diabetes: a randomised, open-label, phase 3a trial. The Lancet Diabetes & Endocrinology, 4(11), 903-915.